Exp. Elacestrant Promising for Pre-Treated HR+, HER2- MBC

moderators

Experimental Elacestrant Shows Promise for Pre-Treated Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer
December 8, 2021
Experimental elacestrant offered better progression-free survival than standard hormonal therapy for post-menopausal women and men diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Read more...